authors
- Atallah, Ehab
- Talpaz, Moshe
- O'brien, Susan
- Rios, Mary Beth
- Arlinghaus, Ralph
- Fernandes-Reese, Sofia
- Kantarjian, Hagop
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
- Overview
- Identity
- Additional Document Info
- View All
Overview
publication date
- January 1, 2002
published in
- Cancer Journal
has subject area
- Antineoplastic Agents
- Benzamides
- Blood Cell Count
- Disease-Free Survival
- Female
- Fusion Proteins, bcr-abl
- Humans
- Imatinib Mesylate
- In Situ Hybridization, Fluorescence
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Lymphocyte Activation
- Middle Aged
- Philadelphia Chromosome
- Piperazines
- Polymerase Chain Reaction
- Prognosis
- Pyrimidines
- Remission Induction
- T-Lymphocytes
- Treatment Outcome